Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 9/20 | 0.35 |
| ▸ | HTR6 | P50406 | 8/20 | 0.35 |
| ▸ | HTR2C | P28335 | 7/20 | 0.35 |
| ▸ | DRD3 | P35462 | 7/20 | 0.35 |
| ▸ | HTR2A | P28223 | 6/20 | 0.35 |
| ▸ | METAP2 | P50579 | 5/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457597 | 0.93 | USP2 (0.40) | USP2SMN1; SMN2DRD2HTR6HTR2C | |
| SCHEMBL13362015 | 0.89 | USP2 (0.37) | USP2SMN1; SMN2DRD2HTR6HTR2C | |
| SCHEMBL5445721 | 0.89 | USP2 (0.41) | USP2SMN1; SMN2DRD2HTR6HTR2C | |
| SCHEMBL5452896 | 0.89 | HTR2C (0.42) | USP2SMN1; SMN2DRD2HTR6HTR2C | |
| SCHEMBL5449041 | 0.87 | DRD2 (0.43) | USP2SMN1; SMN2DRD2HTR6HTR2C | |
| SCHEMBL3323926 | 0.87 | GPR52 (0.37) | USP2SMN1; SMN2DRD2HTR6HTR2C | |
| SCHEMBL5466786 | 0.86 | SIGMAR1 (0.42) | USP2SMN1; SMN2DRD2HTR6HTR2C | |
| SCHEMBL5458151 | 0.86 | LTA4H (0.43) | USP2SMN1; SMN2DRD2HTR6HTR2C | |
| SCHEMBL5448741 | 0.86 | USP2 (0.39) | USP2SMN1; SMN2DRD2HTR6HTR2C | |
| SCHEMBL5459252 | 0.86 | HTR2A (0.37) | USP2SMN1; SMN2DRD2HTR6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225276-A1 | 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | claimed |
| EP-1687005-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | claimed |
| WO-2005051398-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | claimed |
| US-20070225276-A1 | 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| EP-1687005-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051398-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225276-A1 | 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents | HTR4, DRD4, SLC6A3 | USP2 4595/4885SMN1; SMN2 2075/4885DRD2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.